Table S1. Additional data of included studies.

Study, year	Randomization time	Blinding	Key exclusion criteria	Definitions		Event adjudication
				Major bleeding	Myocardial infarction
Keith, 2002	Acute phase	NA	A	TIMI criteria	B	NA
Harvey, 2006	NA	NA	NA	TIMI criteria	C	D
Zeymer, 2006	Non RCT	NA	NA	NA	NA	NA
Li, 2012	Non RCT	NA	E	F	G	NA

A, Exclusion criteria included the presence of a left bundle-branch block or pacemaker, persistent ST-segment elevation, angina with an established precipitating cause (e.g., heart failure or tachydysrhythmia), contraindications to anticoagulation, or a creatinine clearance rate of less than 30 mL per minute; B, defined by electrocardiogram and serum cardiac markers criteria; C, the diagnosis of periprocedural MI required a total CK or CK-MB level >3 times the upper limit of normal and at least 50% above the preprocedural level; D, a clinical events committee blinded to the patients' randomization; E, STEMI, NSTEMI with bare metal stenting or without stenting, contraindication to antithrombotic agents, known bleeding disorders, thrombocytopenia (<100×10⁹/L), administration of oral anticoagulants, conservative treatment without PCI, infarction related to the grafted vessel, and estimated life expectancy of less than 12 months; F, major bleeding was defined as any intracranial bleeding, bleeding associated with the need for blood transfusion, or any other clinically relevant bleeding as judged by the investigator; G, recurrent myocardial infarction was defined as the development of either pathologic Q waves in at least two contiguous leads or an increase in the creatine kinase level to more than twice the upper limit of normal with an elevation of creatine kinase-MB isoenzyme.